AVEO AVEO Pharmaceuticals Inc.

0.75
-0.01  -1%
Previous Close 0.76
Open 0.78
Price To Book 6.29
Market Cap 121,329,932
Shares 160,744,478
Volume 702,968
Short Ratio
Av. Daily Volume 2,061,555
Stock charts supplied by TradingView

NewsSee all news

  1. AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,

  2. AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at

  3. AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

    AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and

  4. AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously Treated With

  5. AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. "This quarter we have made meaningful progress toward our goal of bringing

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2H 2020.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 final data presented at ESMO 2019.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
NDA to be filed in 1Q 2020. Will withdraw if overall survival data in 2Q 2020 yields an OS HR above 1.00.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 2 trial initiation announced November 7, 2019.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)
Phase 1/2 trial initiation announced September 30, 2019.
FOTIVDA (Tivozanib) and IMFINZI (Durvalumab)
Hepatocellular carcinoma (HCC)

Latest News

  1. AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,

  2. AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at

  3. AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

    AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and

  4. AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously Treated With

  5. AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. "This quarter we have made meaningful progress toward our goal of bringing

  6. AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

    AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF) inhibitory

  7. AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

    - NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – - Company Plans Final OS Analysis in 2Q20 - AVEO Oncology (NASDAQ:AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug

  8. AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective

  9. AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at

  10. Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  11. AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - AVEO Oncology